REG - AstraZeneca PLC - AstraZeneca prices a $2bn bond offering

AstraZenecaAnnouncement

26/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260226:nRSZ4520Ua&default-theme=true

RNS Number : 4520U  AstraZeneca PLC  26 February 2026

26 February 2026

 

AstraZeneca prices a $2bn bond offering

 

AstraZeneca PLC ("AstraZeneca") announces that its wholly owned subsidiary
AstraZeneca Finance LLC, priced a three tranche global bond offering totalling
$2bn on 25 February 2026. The offering is expected to close on 2 March 2026,
subject to customary closing conditions. The transaction, which is a global
offering registered with the U.S. Securities and Exchange Commission ("SEC"),
consists of the following three tranches:

Notes issued by AstraZeneca Finance LLC and fully and unconditionally
guaranteed by AstraZeneca

·    $0.65bn of fixed rate notes with a coupon of 4.000%, maturing 2 March
2031;

·    $0.60bn of fixed rate notes with a coupon of 4.300%, maturing 2 March
2033; and

·    $0.75bn of fixed rate notes with a coupon of 4.600%, maturing 2 March
2036.

AstraZeneca expects to use the net proceeds of the offering for general
corporate purposes, which may include the refinancing of existing
indebtedness.

 

BofA Securities, Inc., Deutsche Bank Securities Inc., HSBC Securities (USA)
Inc. and Mizuho Securities USA LLC acted as joint book-running managers on the
transaction.

 

The notes will be issued under AstraZeneca's effective shelf registration
statement on Form F-3, which AstraZeneca and AstraZeneca Finance LLC filed
with the SEC on 19 March 2024. The offering is being made solely by means of
the prospectus contained within that shelf registration statement, along with
a prospectus supplement forming part of the effective registration statement,
which investors should read.

 

A copy of the prospectus supplement and accompanying prospectus relating to
the offering can be obtained by contacting BofA Securities, Inc. by telephone
at +1-800-294-1322; Deutsche Bank Securities Inc. toll-free at
+1-800-503-4611; HSBC Securities (USA) Inc., by telephone at +1-866-811-8049;
or Mizuho Securities USA LLC, by telephone at +1 866-271-7403. Readers may
also download these documents for free by visiting the Electronic Data
Gathering, Analysis, and Retrieval (EDGAR) system on the SEC website at
www.sec.gov (http://www.sec.gov) .

 

This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy the securities described herein, nor shall there be any sale
of these securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction.

 

The bond issuance does not impact AstraZeneca's financial guidance for 2026.

 

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IODFFFVVFDIEFIR



            Copyright 2019 Regulatory News Service, all rights reserved